Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Tolerability and efficacy study of P2X7 inhibition in experimental Charcot-Marie-Tooth type 1A (CMT1A) neuropathy.

Neurobiology of disease - 1 Nov 2016

Sociali Giovanna, Visigalli Davide, Prukop Thomas, Cervellini Ilaria, Mannino Elena, Venturi Consuelo, Bruzzone Santina, Sereda Michael W, Schenone Angelo

Abstract excerpt

Charcot-Marie-Tooth 1A (CMT1A) is a demyelinating hereditary neuropathy for which pharmacological treatments are not yet available. An abnormally high intracellular Ca(2+) concentration was observed in Schwann cells (SC) from CMT1A rats, caused by the PMP22-mediated overexpression of the P2X7 purinoceptor. The purpose of this study was to investigate the tolerability and therapeutic potential of a pharmacological...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Axons
Share to Charcot-Marie-Tooth Disease

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Demyelinating Diseases

Share to Myelin Proteins

Share to Rats, Sprague-Dawley

Share to Rats, Transgenic

Share to Receptors, Purinergic P2X7

Share to Schwann Cells

Source

Identifiers

PMID: 27431093
DOI: 10.1016/j.nbd.2016.07.017

Genes

PMP22

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Tolerability and efficacy study of P2X7 inhibition in experimental Charcot-Marie-Tooth type 1A (CMT1A) neuropathy.PMID 27431093Read ↗

The Current State of Charcot-Marie-Tooth Disease Treatment.Semantic proximity Read ↗

Polytherapy with a combination of three repurposed drugs (PXT3003) down-regulates Pmp22 over-expression and improves myelination, axonal and functional parameters in models of CMT1A neuropathySemantic proximity Read ↗

Farnesol Ameliorates Demyelinating Phenotype in a Cellular and Animal Model of Charcot-Marie-Tooth Disease Type 1A.Semantic proximity Read ↗

Gene therapy and other novel treatment approaches for Charcot-Marie-Tooth disease.Semantic proximity Read ↗

The Current State of Charcot–Marie–Tooth Disease TreatmentSemantic proximity Read ↗

Challenges in Treating Charcot-Marie-Tooth Disease and Related Neuropathies: Current Management and Future PerspectivesSemantic proximity Read ↗

Treatment of Charcot-Marie-Tooth neuropathies.Semantic proximity Read ↗

Early abnormalities in sciatic nerve function and structure in a rat model of Charcot-Marie-Tooth type 1A disease.Semantic proximity Read ↗

P2X7 Receptor Antagonism as a Potential Therapy in Amyotrophic Lateral SclerosisSemantic proximity Read ↗

Early targeting of endoneurial macrophages alleviates the neuropathy and affects abnormal Schwann cell differentiation in a mouse model of Charcot‐Marie‐Tooth 1ASemantic proximity Read ↗

Challenges in modelling the Charcot-Marie-Tooth neuropathies for therapy development.Semantic proximity Read ↗

PMP22 antisense oligonucleotides reverse Charcot-Marie-Tooth disease type 1A features in rodent modelsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.